Autolus Therapeutics Plc (AUTL)
1.88
-0.08
(-4.08%)
USD |
NASDAQ |
Sep 11, 16:00
1.885
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value : 665.07M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 665.07M |
| September 10, 2026 | 686.36M |
| September 09, 2026 | 705.00M |
| September 08, 2026 | 726.29M |
| September 04, 2026 | 760.89M |
| September 03, 2026 | 774.20M |
| September 02, 2026 | 760.89M |
| September 01, 2026 | 779.52M |
| August 31, 2026 | 790.17M |
| August 28, 2026 | 787.51M |
| August 27, 2026 | 792.83M |
| August 26, 2026 | 784.84M |
| August 25, 2026 | 814.12M |
| August 24, 2026 | 787.51M |
| August 21, 2026 | 806.14M |
| August 20, 2026 | 819.45M |
| August 19, 2026 | 840.74M |
| August 18, 2026 | 774.20M |
| August 17, 2026 | 771.54M |
| August 14, 2026 | 736.94M |
| August 13, 2026 | 755.57M |
| August 12, 2026 | 728.95M |
| August 11, 2026 | 784.84M |
| August 10, 2026 | 715.64M |
| August 07, 2026 | 726.29M |
| Date | Value |
|---|---|
| August 06, 2026 | 697.01M |
| August 05, 2026 | 670.39M |
| August 04, 2026 | 683.70M |
| August 03, 2026 | 649.10M |
| July 31, 2026 | 561.27M |
| July 30, 2026 | 571.91M |
| July 29, 2026 | 553.28M |
| July 28, 2026 | 550.62M |
| July 27, 2026 | 553.28M |
| July 24, 2026 | 550.62M |
| July 23, 2026 | 569.25M |
| July 22, 2026 | 547.96M |
| July 21, 2026 | 554.61M |
| July 20, 2026 | 537.31M |
| July 17, 2026 | 547.96M |
| July 16, 2026 | 553.28M |
| July 15, 2026 | 566.59M |
| July 14, 2026 | 550.62M |
| July 13, 2026 | 558.61M |
| July 10, 2026 | 593.21M |
| July 09, 2026 | 614.50M |
| July 08, 2026 | 617.16M |
| July 07, 2026 | 593.21M |
| July 06, 2026 | 598.53M |
| July 02, 2026 | 585.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bicycle Therapeutics Plc | -300.39M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | 60.85B |
| Mereo BioPharma Group Plc | 15.61M |
| Evaxion AS | 19.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.18M |
| Revenue (Quarterly) | 45.77M |
| Total Expenses (Quarterly) | 84.95M |
| EPS Diluted (Quarterly) | -0.1472 |
| Gross Profit Margin (Quarterly) | 55.20% |
| Profit Margin (Quarterly) | -85.60% |
| Earnings Yield | -55.86% |
| Normalized Earnings Yield | -55.81 |